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ABSTRACT
Aims To determine if
 ► Very low dose mydriatic eye microdrop regimen suffi-
ciently dilates the pupil (above 4.1 mm) compared 
with the currently used low dose mydriatic eye 
microdrop regimen.
 ► Cardiovascular, gastrointestinal and respiratory 
adverse effects occur following eye drop instillation.
Methods Seventeen premature infants were recruited 
into this prospective, randomised controlled pilot trial in 
January 2017 to November 2018. Data were collected 
from the single- centre Neonatal Intensive Care Unit, 
Dunedin Hospital, New Zealand. The inclusion criteria 
were birth weight less than 1500 g or gestational age 
less than 31 weeks, or any premature infant requiring red 
reflex testing. Infants were randomised to receive either 
phenylephrine 1% or 0.5% and cyclopentolate 0.2% 
or 0.1%, 1 microdrop in both eyes. Efficacy outcome 
measures were pupil size at retinopathy of prematurity 
eye examination (ROPEE) and ophthalmologist rating of 
ease of screen.
Results All participants had sufficient pupillary dilation 
for a successful ROPEE. Ophthalmologists rated the 
ROPEE as easy for 90% of all examinations. Pupil dilation 
measurements at the time of examination, mean±SD, 
4.8±0.2 (95% CI 4.5 to 5.2) mm for treatment A and 
5±0.2 (95%CI 4.6 to 5.4) mm for treatment B (p=0.61). 
There were no statistically significant differences 
between the groups for safety data.
Conclusions Very low dose microdrop administration 
of phenylephrine and cyclopentolate appears to be 
effective at sufficiently dilating the neonatal pupil 
for ROPEEs. Low dose and very low dose microdrop 
mydriatic regimens may also reduce the risk of unwanted 
adverse effects associated with these medicines.
Trial registration number Australian New 
Zealand Clinical Trials Registry (reference 
ACTRN12616001266459p).
INTRODUCTION
Retinopathy of prematurity (ROP) (retinopathy of 
prematurity) is a major cause of preventable blind-
ness in children. Because of the risk of permanent 
blindness, routine eye examinations in very preterm 
neonates (less than 31 weeks) are carried out in 
neonatal units in New Zealand and internationally. 
With early detection of retinopathy, timely inter-
ventions can effectively treat this condition.
Sufficient pupillary dilation is needed to obtain 
an adequate view of the retina, and mydriatic medi-
cines play an essential role in dilating the pupil. 
Both phenylephrine and cyclopentolate mydriatic 
eye drops are commonly used; however, they have 
been associated with unwanted side effects such 
as hypotension,1 bradycardia,1 2 desaturations,3 
apnoea,4 5 periorbital pallor,5 6 feed intolerance7 
and necrotising enterocolitis (NEC).2 8–12 There are 
no published data that have established efficacy of 
the reference treatment; however, the microdrop 
regimen has been used for a number of years with 
successful retinopathy of prematurity eye examina-
tions (ROPEEs) occurring. Multiple pilot studies 
What is already known on this topic?
 ► Mydriatics are commonly used to dilate the 
neonatal pupil for retinopathy of prematurity 
eye examinations, but appropriate dose ranging 
studies have not been undertaken. Available 
evidence suggests that some of these mydriatic 
doses are too high. The use of microdrops has 
been suggested as a way of minimising harm, 
but there has not been a randomised controlled 
trial (RCT) investigating the efficacy and safety 
of low dose microdrops. A pilot RCT study is 
needed to provide experience and statistical 
information for use in designing a definitive 
trial.
What this study adds?
 ► In this randomised controlled pilot trial that 
included 16 premature infants, all infants had 
sufficient pupil dilation with low dose and very 
low dose, single microdrop administration of 
phenylephrine and cyclopentolate.
 ► Low dose microdrops are a promising 
alternative to standard drops. Microdrop 
administration minimises systemic exposure to 
mydriatics. Reducing the dose of the mydriatic 






































































2 Kremer LJ, et al. Arch Dis Child 2020;0:1–6. doi:10.1136/archdischild-2019-318733
Original research
have suggested efficacy with 1 and/or 2 drops of phenylephrine 
1% and cyclopentolate 0.2%.1 7 13–16
The aim of the study was to explore whether similar efficacy 
could be expected from a lower dose of mydriatic compared 
with the current microdrop mydriatic regimen, potentially with 
the advantage of fewer adverse effects.
The primary hypothesis was to investigate if 2 microdrop 
regimens, low dose (treatment A; phenylephrine 1% and cyclo-
pentolate 0.2%, 1 microdrop in both eyes) and very low dose 
(treatment B; phenylephrine 0.5% and cyclopentolate 0.1%, 1 
microdrop in both eyes), sufficiently dilates the pupil for retinal 
examination in premature infants. The hypothesis that is being 
tested is that very low dose (treatment B) sufficiently dilates the 
pupil above 4.1 mm with a dilation profile that is not statistically 
inferior to the low dose regimen (treatment A) (online supple-
mental appendix 1).
The study also aimed to develop outcome methods for 
measuring the efficacy of the mydriatics in future studies. This 
information could then be used to design a non- inferiority, 
confirmatory study.
METHODS
This single- centre, prospective, randomised controlled trial 
was conducted at the Neonatal Intensive Care Unit, Dunedin 
Hospital, New Zealand from January 2017 to November 2018.
The inclusion criteria were birth weight less than 1500 g or 
gestational age less than 31 weeks, or any premature infant 
requiring red reflex testing. The exclusion criteria were ROP 
greater than stage 2, defined by an elevated ridge17; any other 
ocular eye condition (eg, infection); and contraindication to 
phenylephrine and/or cyclopentolate. Parents/whānau of the 
infant were able to withdraw at any time point, for any reason, 
during the study.
After parent/whānau informed consent was obtained by 
the research nurse or by the infant’s lead neonatologist, 16 
premature infants were enrolled in the study. The infants were 
randomised to treatment according to computer- generated 
block randomisation in sequentially numbered, opaque and 
sealed envelopes of two blocks of eight (online supplemental 
appendix 2).
The demographic information that was collected was sex, 
ethnicity (according to neonates whānau/parent(s)/caregiver(s)), 
dark or light iris colour, gestational age, weight, level of respira-
tory support (if any) and grade of ROP (classified by the Inter-
national Classification of Retinopathy of Prematurity) prior to 
study ROPEE.17
Nursing staff prepared the eye drops by diluting phenyleph-
rine and cyclopentolate with hypromellose 0.5% (Methopt), 
therefore compounding a combination eye drop that required 
just one administration per eye. As per routine standard practice 
in the Dunedin Hospital Neonatal Unit, microdrop administra-
tion was achieved by using a 24G cannula, removing the needle 
and attaching the cannula to a 3 mL syringe. Eye drops were 
administered approximately 45 min prior to ROPEE.
The primary efficacy outcome measure was pupil size at 
ROPEE (approximately 45 min from administration). Analysis 
of mean pupil size between groups occurred to see if there was a 
difference in means. Pupil measurements were also recorded at 
baseline, 20 min, 90 min and 120 min.
The secondary efficacy outcome measures that were compared 
between groups were as follows:
 ► Successful ROPEE performed by the ophthalmologist. These 
outcome measurements are at similar times to published 
studies; however, these studies used standard drops and not 
microdrops.14 15
 ► In addition, the ophthalmologist scores on the ease of the 
ROPEE on the scale of very easy, easy, no difference, diffi-
cult or very difficult. These outcomes measures are similar to 
those reported by Lux et al.18
 ► Photos of both eyes were obtained using a camera, with the 
eye illuminated.
 ► Photos were imported into the GIMP V.2.8.20 image 
manipulation program, where the measure tool was used to 
measure the pupil diameter and compare with the metric 
graduated colour tool.19
A secondary objective was to investigate cardiovascular, 
gastrointestinal and respiratory effects following the eye drop 
administration. These were analysed using descriptive statistics 
(online supplemental appendix 3).
Statistical methods
Sample size
Sample size calculation was based on the primary efficacy 
outcome measure using descriptive statistics from the litera-
ture, including mean (SD) within- person dilation pre- treatment 
between eyes, mean (SD) post- treatment dilation for each treat-
ment, proportion that sufficiently dilated for each treatment, 
and range of dilation (mm) measured for “sufficient” and “not 
sufficient”.15
Given that pupils dilate from a mean diameter of 3.1 mm to 
5.4 mm15 and dilation of at least 4 mm is required for a successful 
examination, it was decided that it would be unacceptable if the 
treatment drops did not dilate the pupils to more than 4.1 mm 
in diameter. SD for the change was not reported, so a conserva-
tive SD=1 was used. We did not expect there to be a difference 
in efficacy between the treatment groups, hence the treatment 
difference was 0. The sample size was then based on the lower 
95% CI for the intervention group not including 4.1 mm. The 
hypothesis test was for non- inferiority, not for superiority. 
Following these considerations and simulation testing, a sample 
size of 16 was determined.
Analysis
Analysis was carried out at the completion of recruitment. For 
efficacy data, predetermined analysis using paired t- test for 
difference between treatments was calculated. A change in dila-
tion from pre- administration to 30 min post- administration was 
calculated for each eye. Difference in change was calculated for 
each infant (test treatment–reference treatment) and the sample 
mean difference and 90% CI was calculated.
Exploratory analysis included Wilcoxon signed- rank test was 
used to analyse the ease of screen, level of ROP and pupil colour.
For safety data, blood pressure and heart rate were analysed 
using summary measures of hourly mean and peak results, feed 
intolerance was described with summary statements and treat-
ment emergent adverse effect (TEAE) results were described by 
proportions.
RESULTS
Baseline demographic and clinical characteristics
Seventeen premature infants were enrolled in this study; nine 
infants randomised to the low dose (intervention A) and eight 
infants randomised to the very low dose (intervention B) 
(CONSORT Flow Diagram, online supplemental appendix 1). 
One infant was enrolled, randomised and received the very low 
dose (treatment B), but was withdrawn from the study, and a 
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replacement of drop- out occurred to ensure 16 data sets. The 
withdrawal was due to an adverse event: very puffy eyes making 
it impossible to collect efficacy data. The adverse event was 
attributed to study procedure (manipulation of the eyelid) and 
not to study treatment.
The majority of the participants were male, and most partici-
pants identified as New Zealand European (87%) and just under 
14% identified as Māori (table 1). Infants who received the very 
low dose group (treatment B) were significantly younger for 
gestational age (GA): GA median 26.3 weeks, compared with 
the low dose group (treatment A), GA median 29 weeks. There 
was no statistically significant difference in birth weight between 
the groups.
The low dose (intervention group A) had more infants with 
chronic lung disease (CLD), which could be explained by their 
older age at the time of ROPEE. More infants in the very low 
dose group (intervention group B) were on CPAP which is 
explained by the younger gestational age of the group. Grade of 
ROP prior to study eye examination is similar in both groups.
Efficacy
Pupil size
There were no statistically significant differences between either 
group at any time point (table 2 and figure 1). All participants 
were included in the analysis at time of ROPEE and both treat-
ments resulted in sufficient pupillary dilatation: mean (95% CI) 
4.83 (4.46 to 5.20) mm for the low dose group (treatment A) 
and 4.96 (4.56 to 5.36) mm for the very low dose group (treat-
ment B). However, the 120 min time point was not analysed 
due to low numbers. These low numbers were because manual 
eye lid retraction was used for all time points (except time of 
ROPEE). At data points at 90 and 120 min (in some cases), the 
infant’s periorbital area had become slightly red and puffy due 
to repeated manual handling. Research staff then opted out of 
collecting data to avoid any possible infant discomfort and harm 
to the delicate skin around the eye area.
Pupil size was measured in every participant at the time of 
ROPEE because at that time point, almost every participant had 
eyelid retractors in, and if the infant was averting their eye, the 
ophthalmologist was able to adjust the eye to a centre view for 
the image capture.
At times other than the ROPEE, it was often difficult 
to obtain usable photos of the eye. Reasons for this were as 
follows: manual eyelid retraction was too difficult because the 
eyelid turned up; the infant averted their eye; periorbital soft 
tissue trauma.
Another reason for missing pupil dilation results was because 
of a change in pupil dilation capture. Initially, we trialled the use 
of a Colvard Pupilometer; however, as soon as the eye piece was 
placed over the infant’s eye, they would close their eye. We then 
trialled a Neuroptics Pupilometer; however, the infant needed 
to hold a fixed gaze for more than 10 s to obtain a reading, 
therefore this method also proved unsuitable. We then sought 
a professional photographer’s assistance in taking photos, and 
with their guidance, were able to obtain adequate photos with a 
ZTE mobile phone camera.
On the screen of the mobile phone, some photos appeared 
sufficient; however, once the photos were viewed in the GIMP 
software, some photos were of insufficient quality to ascertain 
a pupillary diameter. Reasons for the poor quality were (1) low 
lighting and (2) reflection off the top of the incubator, both 
resulting in the diameter of the pupil not able to be easily identi-
fied. Some photos could not be used because the measuring tape 
was not visible to measure the pupillary diameter against.
Table 1 Baseline demographic and clinical characteristics for study participants
Low dose—intervention group A: phenylephrine 
1% and cyclopentolate 0.2%,
1 microdrop (n=9)
Very low dose—intervention group B: 
phenylephrine 0.5% and cyclopentolate 0.1%,
1 microdrop (n=7) P value
Gestational age (weeks)
  Median, range (95% CI) 29, 26.6–31.1 (27.6 to 29.7) 26.3, 25.1–28 (25.4 to 27.6) 0.005
Birth weight (g)
  Median, range (95% CI) 1175, 770–1410 (915.3 to 1274.7) 950, 640–1070 (785.4 to 1037.5) 0.087
Sex, n (%)
  Male 7 (78) 6 (86)
  Female 2 (22) 1 (14)
Ethnicity, n (%)
  New Zealand European 8 (89) 6 (86)
  Māori 1 (14)
  Pacific Peoples 1 (11)
Iris pigment, n (%)
  Dark 3 (34) 4 (57)
  Light 6 (66) 3 (43)
Grade of ROP, n (%)
  Unknown (first EE) 3 (34) 4 (57)
  None 5 (55) 3 (43)
  Level 1 1 (11)
Level of respiratory support, n (%)
  None 6 (67) 1 (14)
  CPAP 2 (22) 5 (72)
  Low flow 1 (11)
  High flow 1 (14)
CPAP, continuous positive airway pressure; EE, eye examination; ROP, retinopathy of prematurity. copyright.
 on O
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The best quality photos were of infants in cots and when a red 
reflex was obtained.
For time points at baseline, ROPEE and 90 min, there were 
no significant differences between pupillary diameter between 
the two intervention groups. Due to the missing data, the mean 
difference in baseline and ROPEE time points were not able to 
be analysed. Missing data were not imputed because more than 
10% of data were missing.
The mean±SD (95% CI) difference in pupillary diameter at 
ROPEE was 0.13±0.6 (95% CI −0.26 to 0.00, p=0.97) mm.
Ophthalmologist ease of screen
All infants in both intervention groups had successful ROPEE 
(table 3). Almost 90% of the ROPEE in both groups were rated 
by the ophthalmologist as very easy, easy or no difference. No 
rating of very difficult was assigned in either groups. Very easy, 
easy and no difference were combined for analysis.
Because there was no statistically significant difference between 
the two groups for ease of screen, the groups were combined for 
exploratory subgroup analysis on ease of screen with eye colour 
and grade of ROP. There was no statistically significant differ-
ence between eye colour and ease of screen, and no statistically 
significant difference between ROP and ease of screen.
Safety
Some physiological data were unavailable when the infants were 
discharged home or transferred to another hospital. One infant 
had cardiovascular and temperature measurements missed due 
to a fire alarm occurrence during the data collection time point.
There were no clinically or statistically significant differences 
between the two groups at any time point for blood pressure or 
temperature recordings (table 4).
Respiratory
There was no change in level of respiratory support from the day 
prior to, on the day of and the day after ROPEE in either group. 
The low dose group (intervention A) had seven complete data 
sets from nine infants. The very low dose group (intervention 
B) had six complete data sets from seven infants. The incom-
plete data set was because of loss to follow- up due to transfer to 
another hospital.
Gastrointestinal
No clinically significant changes with feed volume, number 
of spills, reflux or distended abdomen were found between 
the two groups. However, one infant in the very low dose 
group (intervention group B) developed NEC, stage 2, 5 days 
after the ROPEE. This infant was born at 25 weeks and 2 
days gestational age, 1180 g birth weight, and had multiple 
medical conditions (eg, patent ductus arteriosus, CLD). The 
infant fully recovered; however, causality was difficult to 
assess due to the complex nature of the infant’s other risk 
factors for developing NEC.
Treatment emergent adverse effects
There were no TEAEs that occurred during the study period. 
Both intervention groups had a complete data set for TEAEs.
DISCUSSION
Both treatments provided sufficient pupillary dilatation to 
enable successful ROPEE. All infants enrolled in the study had 
sufficient pupil dilation (mean pupillary dilation (mm) ±SE 
(95% CI) above 4.1 mm (low dose treatment A 4.83±0.18 
Table 2 Mean pupillary dilation (mm) ±SE and 95% CI at baseline, 20 min, immediately prior to ROPEE, 90 min and 120 min
Low dose—intervention group A: 
phenylephrine 1% and cyclopentolate 0.2%,
1 microdrop (n=9)
Very low dose—intervention group B: 
phenylephrine 0.5% and cyclopentolate 0.1%,
1 microdrop (n=7) P value
Baseline
  Mean pupillary dilation (mm) ±SE (95% CI) 2.93±0.2 (2.43 to 3.41) 3.4±0.13 (2.97 to 3.77) 0.15
  No of pupil measurements (%) 7/18 (39) 4/14 (29)
20 min
  Mean pupillary dilation (mm) ±SE 4.7±0.54 4.5
  No of pupil measurements (%) 5/18 (28) 1/14 (7)
ROPEE (approximately 45 min)
  Mean pupillary dilation (mm) ±SE (95% CI) 4.83±0.18 (4.46 to 5.20) 4.96±0.18 (4.56 to 5.36) 0.61
  No of pupil measurements (%) 18/18 (100) 14/14 (100)
  Difference between means (mm) ±SE (95% CI) 0.13±0.6 (−0.26 to 0.00) 0.97
90 min
  Mean pupillary dilation (mm) ±SE (95% CI) 4.58±0.28 (3.96 to 5.2) 5.5±0.50 (−0.88 to 11.88) 0.23
  No of pupil measurements (%) 12/18 (67) 2/14 (14)
120 min
  Mean pupillary dilation (mm) ±SE 3.75±0.11 – –
  No of pupil measurements (%) 6/18 (33) 0/14 (0)
Figure 1 Average pupillary dilation over time showing sufficient 
pupillary dilation at time of ROPEE.
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(4.46 to 5.20) mm, very low dose treatment B 4.96±0.18 
(4.56 to 5.36) mm). All infants enrolled in the study had 
successful ROPEE.
Although these results should be interpreted with care, due 
to the small sample size, the results suggest that single admin-
istration and very low microdrop doses of phenylephrine and 
cyclopentolate are effective at sufficiently dilating the pupil for 
ROPEE. This has implications for reducing the risk of systemic 
exposure of these mydriatic medicines to the premature infant, 
and therefore potentially reducing the risk of adverse effects.15 20
Other authors have found similar results with the use of 
phenylephrine 1% and cyclopentolate 0.2% (1 to 2 standard 
drops),14–16 but there are no publications evaluating microdrop 
administration of these medicines.
No statistically or clinically significant effect was noticed with 
infants with darker iris colour; however, there is evidence in 
the literature suggesting that infants with dark iris colour may 
require higher doses of mydriatic medicines.7 13 21 This will be of 
particular importance for indigenous people of Aotearoa, New 
Zealand.
Cardiovascular, gastrointestinal and respiratory systems 
were monitored for adverse effects, and there were no clinical 
or statistical differences between the two groups, except for 
the 25 weeks GA infant who developed NEC. This study was 
not sufficiently powered to detect non- inferiority of the safety 
profile of the two treatment groups.
The results of this study can be used to inform the design of 
a larger RCT, in particular how to obtain good photos of the 
neonatal eye. Eventually, we established that red reflex photos, 
with retractors in place, was the best method for collecting data 
on pupil diameter. We observed that multiple manual retraction 
of the eye lids caused periorbital soft tissue trauma; therefore, 
Table 3 Ease of screen with subgroup analysis on eye colour, and grade of retinopathy of prematurity
Low dose—intervention group A: 
phenylephrine 1% and cyclopentolate 0.2%,
1 microdrop (n=9)
Very low dose—intervention group B: 
phenylephrine 0.5% and cyclopentolate 0.1%,
1 microdrop (n=7)
Wilcoxon signed- rank test 
p value
Ease of screen
  Easy 8 (89) 6 (86)
  Difficult 1 (11) 1 (14)
Eye colour 0.053
  Dark+easy 2 3
  Light+easy 6 3
  Dark+difficult 1 0
  Light+difficult 0 1
Grade of ROP 1.00
  None+easy 5 2
  Grade 1+easy 1 0
  Unknown+easy 2 4
  None+difficult 0 1
  Grade1+difficult 0 0
  Unknown (first EE)+difficult 1 0
EE, eye examination; ROP, retinopathy of prematurity.
Table 4 Cardiovascular results at baseline, 20 min and prior to ROPEE (temperature results at baseline and prior to ROPEE)
Low dose—intervention group A: 
phenylephrine 1% and cyclopentolate 0.2%,
1 microdrop (n=9)
Very low dose—intervention group B: 
phenylephrine 0.5% and cyclopentolate 0.1%,
1 microdrop (n=7) P value
Mean blood pressure (mm Hg)
  Baseline
   Mean BP (mm Hg) ±SE (95% CI) 62±4 (53 to 72) 54±2 (49 to 59) 0.1295
   No of BP measurements (%) 9/9 (100) 7/7 (100)
  20 min
   Mean BP (mm Hg) ±SE (95% CI) 54±5 (43 to 65) 56±4 (46 to 66) 0.7265
   No of BP measurements (%) 8/9 (89) 6/7 (86)
  Prior to ROPEE (approximately 45 min)
   Mean BP (mm Hg) ±SE (95% CI) 55±6 (40 to 69) 52±4 (43 to 61) 0.7491
   No of BP measurements (%) 8/9 (89) 7/7 (100)
Temperature (°C)
  Baseline
   Mean temperature (°C) ±SE (95% CI) 36.8±0.07 (36.6 to 37) 36.9±0.3 (36.25 to 37.5) 0.6901
   No of temperature measurements (%) 9/9 (100) 7/7 (100)
  Prior to ROPEE (approximately 45 min)
   Mean temperature (°C) ±SE (95% CI) 36.8±0.8 (36.6 to 37) 36.9±0.1 (36.7 to 37) 0.6415
   No of temperature measurements (%) 9/9 (100) 6/7 (86)
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we would not recommend this methodology for any future 
studies. In addition, the true end point for the larger RCT will 
be whether the ophthalmologist is able to perform the eye exam-
ination, rather than the pupillary diameter measurement.
Limitations
The study participants were majority New Zealand European 
male infants; therefore, results may not be generalised to the 
entire population.
The pupillary measurement method is an imprecise estimate, 
therefore should be interpreted with caution.
Further research
A sufficiently powered non- inferiority confirmatory RCT is 
needed to evaluate these 2 microdrop regimens for efficacy and 
safety. Data from this study may be used to inform a sample size 
calculation.
CONCLUSION
Very low dose microdrop administration of phenylephrine and 
cyclopentolate appears to be effective for sufficiently dilating the 
neonatal pupil for retinopathy of prematurity eye examinations. 
In addition, low dose and very low dose microdrop mydriatic 
regimens may also reduce the risk of unwanted adverse effects 
associated with these medicines.
A sufficiently powered non- inferiority RCT comparing these 
low and very low dose microdrop regimens is required to 
confirm both the efficacy and safety. These results, however, 
represent a transferable methodology for assessment of pupil 
diameter in future studies.
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Web Appendix 1 
Therefore the PICO components are as follows: 
 P (population) = premature infants who meet the retinopathy of prematurity eye 
examination criteria or red reflex testing 
 I (intervention) = very low dose mydriatic regimen; phenylephrine 0.5% and cyclopentolate 
0.1%, 1 microdrop in both eyes 
 C (comparison) = low dose mydriatic regimen; phenylephrine 1% and cyclopentolate 0.2%, 
1 microdrop in both eyes 
 O (outcome) = pupil dilation, ease of retinopathy of prematurity eye examination, 
cardiovascular, respiratory, and gastrointestinal system adverse effects  
Web Appendix 2 
Block randomisation number list was prepared by an investigator (DR) who had no clinical 
involvement in the trial.  The envelopes were opened sequentially, and only after the envelope had 
been irreversibly assigned to the participant.  The study was single-blind and the research nurse and 
the nursing staff compounding the eye drops were aware of the randomisation.  To minimise 
outcome measurement bias, all other staff and parents/whānau were masked to the treatment 
allocation. 
Allocation concealment was maintained with a strict implementation of an allocation sequence by 
DR and carried out by the research nurse, without foreknowledge of the intervention assignments.  
The two treatments were of identical appearance.  Masking was maintained until after data analysis. 
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Web Appendix 3 
Mean blood pressure at baseline, and immediately prior to ROPEE at approximately 45 min post eye 
drop instillation, were recorded to identify cardiovascular effects.  These outcome measures are 
similar to published studies1,2 
Oxygen requirements 24 hours prior to, on the day of, and 24 hours post-administration were 
collected to identify respiratory effects. 
Data on feed volume, number of spills, gastrointestinal medical conditions, and nutrition (e.g. breast 
milk, parenteral nutrition), were collected for the day prior to, on the day of, and 7 days post ROPEE, 
to identify gastrointestinal effects. 
Any treatment emergent adverse events (TEAE) were recorded. 
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